TIMOPTIC OCUDOSE Rx
Generic Name and Formulations:
Timolol (as maleate) 0.25%, 0.5%; (0.2mL/dose); oph soln; preservative-free.
Bausch Health Companies Inc.
Indications for TIMOPTIC OCUDOSE:
Elevated intraocular pressure in ocular hypertension or open-angle glaucoma.
Adults and Children:
<2yrs: not established. ≥2yrs: Initially 1 drop of 0.25% twice daily; max 1 drop of 0.5% twice daily. Transfer from other drugs, see full labeling.
Greater than 1st-degree AV block. Uncompensated cardiac failure. Cardiogenic shock. Sinus bradycardia. History of bronchospasm. Bronchial asthma. Severe COPD.
Not for use as sole agent in angle-closure glaucoma. Poor cardiac reserve should be controlled with digitalis and diuretics. Diabetes. Presbyopia. May mask hypoglycemia or thyrotoxicosis. Myasthenia gravis. Cerebrovascular insufficiency. Measure intraocular pressure after 4 weeks of treatment. Avoid abrupt cessation. Discontinue at 1st sign of cardiac failure and before surgery. Pregnancy. Nursing mothers: not recommended.
May potentiate systemic β-blockers, reserpine, hypoglycemics and mydriatic effect of topical epinephrine. Additive cardiac and pulmonary effects with anticholinesterase miotics. May antagonize bronchodilation from β-adrenergic agonists. May cause conduction defects with calcium channel blockers, digoxin. May be potentiated by CYP2D6 inhibitors (eg, quinidine, SSRIs).
Ocular irritation, sensitization, rash, dizziness, blurred vision, corneal anesthesia, headache, GI upset, paresthesias. Systemic β-blocker effects (bradycardia, arrhythmias, hypotension, bronchospasm, heart failure). Aphakic maculopathy (rare).
Soln—contact supplier; Ocudose—60; XE—2.5mL, 5mL
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds